EUVIMEDEUVIMED entdecken
Crossref

Antineoplastic Therapy Administration Safety Standards for Adult and Pediatric Oncology: ASCO-ONS Standards

Robert D Siegel iD, Kristine B LeFebvre iD, Sarah Temin iD, Amy Evers, Lisa Barbarotta, Ronda M Bowman iD, Alexandre Chan iD, David W Dougherty, Michael Ganio, Bradley Hunter iD, Meredith Klein, Tamara P Miller und 8 weitere

JCO Oncology Practice · 2024-10 · 20 (10) · 1314-1330

DOI: 10.1200/op.24.00216 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Oncology Practice, 2024-10. Verfasst von Robert D Siegel und 19 weiteren Autor:innen. Beteiligte Einrichtung: Bon Secours St Francis Cancer Center, Greenville, SC. Hauptthemen laut MEDLINE: Antineoplastic Agents, Neoplasms. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 90 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

ASCO Standards are evidence-based standards to provide frameworks for best practices in cancer care, following the standards development process as outlined in the ASCO Standards Policies and Procedures Manual . ASCO Standards follow the ASCO Conflict of Interest Policy for Clinical Practice Guidelines . Standards and other guidance (“Guidance”) provided by ASCO is not a comprehensive or definitive guide to treatment options. It is intended for voluntary use by providers and should be used in conjunction with independent professional judgment. Guidance may not be applicable to all patients, interventions, diseases or stages of diseases. Guidance is based on review and analysis of relevant literature, and is not intended as a statement of the standard of care. ASCO does not endorse third-party drugs, devices, services, or therapies and assumes no responsibility for any harm arising from or related to the use of this information. See complete disclaimer in Appendix 1 (online only) for more. PURPOSE To update the ASCO-Oncology Nursing Society (ONS) standards for antineoplastic therapy administration safety in adult and pediatric oncology and highlight current standards for antineoplastic therapy for adult and pediatric populations with various routes of administration and location. METHODS ASCO and ONS convened a multidisciplinary Expert Panel with representation of multiple organizations to conduct literature reviews and add to the standards as needed. The evidence base was combined with the opinion of the ASCO-ONS Expert Panel to develop antineoplastic safety standards and guidance. Public comments were solicited and considered in preparation of the final manuscript. RESULTS The standards presented here include clarification and expansion of existing standards to include home administration and other changes in processes of ordering, preparing, and administering antineoplastic therapy; the advent of immune effector cellular therapy; the importance of social determinants of health; fertility preservation; and pregnancy avoidance. In addition, the standards have added a fourth verification. STANDARDS Standards are provided for which health care organizations and those involved in all aspects of patient care can safely deliver antineoplastic therapy, increase the quality of care, and reduce medical errors. Additional information is available at www.asco.org/standards and www.ons.org/onf .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsNeoplasmsHumansAdultChildMedical OncologyPatient SafetyFemalePediatrics

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Bon Secours St Francis Cancer Center, Greenville, SC.
  • Oncology Nursing Society (ONS), Pittsburg, PA.
  • American Society of Clinical Oncology (ASCO), Alexandria, VA.
  • University of Pennsylvania Health System, Philadelphia, PA.
  • Smilow Cancer Hospital and Yale Cancer Center, New Haven, CT.
  • University of California, Irvine, Chao Family Comprehensive Cancer Center, National Cancer Centre Singapore, Irvine, CA.

ORCID-Profile: Robert D Siegel, Kristine B LeFebvre, Sarah Temin, Ronda M Bowman, Alexandre Chan, Bradley Hunter, Therese Marie Mulvey, Amanda Ouzts, Maritza Salazar-Abshire, Christine Marie Sydenstricker

Zitieren

APA

Siegel, R. D., LeFebvre, K. B., Temin, S., Evers, A., Barbarotta, L., Bowman, R. M., Chan, A., Dougherty, D. W., Ganio, M., Hunter, B., Klein, M., Miller, T. P., Mulvey, T. M., Ouzts, A., Polovich, M., Salazar-Abshire, M., Stenstrup, E. Z., Sydenstricker, C. M., Tsai, S., & Olsen, M. M. (2024). Antineoplastic Therapy Administration Safety Standards for Adult and Pediatric Oncology: ASCO-ONS Standards. JCO Oncology Practice, 20(10), 1314-1330. https://doi.org/10.1200/op.24.00216

Vancouver

Siegel RD, LeFebvre KB, Temin S, Evers A, Barbarotta L, Bowman RM, et al. Antineoplastic Therapy Administration Safety Standards for Adult and Pediatric Oncology: ASCO-ONS Standards. JCO Oncology Practice. 2024;20(10):1314-1330. doi:10.1200/op.24.00216

BibTeX
@article{Siegel2024,
  author = {Siegel, Robert D and LeFebvre, Kristine B and Temin, Sarah and Evers, Amy and Barbarotta, Lisa and Bowman, Ronda M and Chan, Alexandre and Dougherty, David W and Ganio, Michael and Hunter, Bradley and Klein, Meredith and Miller, Tamara P and Mulvey, Therese Marie and Ouzts, Amanda and Polovich, Martha and Salazar-Abshire, Maritza and Stenstrup, Elaine Z and Sydenstricker, Christine Marie and Tsai, Susan and Olsen, MiKaela M},
  title = {Antineoplastic Therapy Administration Safety Standards for Adult and Pediatric Oncology: ASCO-ONS Standards},
  journal = {JCO Oncology Practice},
  year = {2024},
  volume = {20},
  number = {10},
  pages = {1314--1330},
  doi = {10.1200/op.24.00216}
}
Kostenlos starten →